Payment overview · 2025
General Payments
$169.85
7 reported records · 5 companies
Healthcare provider profile · identity verified
Mark L Mankins, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OLNEY, TX · NPI 1952416158
Verified facts
What the public records show
CMS Open Payments records show Mark L Mankins, M.D. received $169.85 in general payments during 2025 across 7 reported records.
Lundbeck LLC accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $56.95 | 33.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.78 | 26.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.02 | 19.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.39 | 10.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.71 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $169.85 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $56.95 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.78 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 85 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 160 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
85 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
160 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 523 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 457 | 115 |
| Lisinopril | Lisinopril | 426 | 115 |
| Gabapentin | Gabapentin | 425 | 89 |
| Potassium Chloride | Potassium Chloride | 422 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 384 | 93 |
| Metformin Hcl | Metformin Hcl | 357 | 80 |
| Furosemide | Furosemide | 343 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 315 | 86 |
| Losartan Potassium | Losartan Potassium | 302 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 264 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 48 |
| Eliquis | Apixaban | 210 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 207 | 54 |
| Tramadol Hcl | Tramadol Hcl | 197 | 57 |
| Celecoxib | Celecoxib | 177 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 34 |
| Meloxicam | Meloxicam | 166 | 55 |
| Allopurinol | Allopurinol | 164 | 36 |
| Ozempic | Semaglutide | 160 | 25 |
| Omeprazole | Omeprazole | 147 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 144 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 139 | 84 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 29 |
| Sertraline Hcl | Sertraline Hcl | 134 | 31 |
| Montelukast Sodium | Montelukast Sodium | 133 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 27 |
| Trazodone Hcl | Trazodone Hcl | 120 | 33 |
| Azithromycin | Azithromycin | 117 | 82 |
| Methocarbamol | Methocarbamol | 104 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 27 |
| Carvedilol | Carvedilol | 97 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 28 |
| Glimepiride | Glimepiride | 94 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 90 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 88 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 17 |
| Methylprednisolone | Methylprednisolone | 85 | 52 |
| Mounjaro | Tirzepatide | 85 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 84 | 20 |
| Ondansetron Odt | Ondansetron | 82 | 39 |
| Alprazolam | Alprazolam | 81 | 19 |
| Cephalexin | Cephalexin | 80 | 53 |
| Doxycycline Hyclate | Doxycycline Hyclate | 80 | 46 |
| Simvastatin | Simvastatin | 79 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 73 | 12 |
| Finasteride | Finasteride | 72 | 16 |
| Januvia | Sitagliptin Phosphate | 72 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 18 |
| Trulicity | Dulaglutide | 70 | suppressed |
| Jardiance | Empagliflozin | 69 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 68 | 22 |
| Prednisone | Prednisone | 68 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 12 |
| Pregabalin | Pregabalin | 64 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 14 |
| Bumetanide | Bumetanide | 62 | 16 |
| Clonidine Hcl | Clonidine Hcl | 62 | 30 |
| Topiramate | Topiramate | 61 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 60 | 16 |
| Synthroid | Levothyroxine Sodium | 60 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 15 |
| Metolazone | Metolazone | 58 | 14 |
| Spironolactone | Spironolactone | 58 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 54 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | suppressed |
| Premarin | Estrogens, Conjugated | 52 | suppressed |
| Levofloxacin | Levofloxacin | 50 | 36 |
| Mupirocin | Mupirocin | 50 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Ibuprofen | Ibuprofen | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 27 |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 12 |
| Metformin Hcl Er | Metformin Hcl | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 26 |
| Amoxicillin | Amoxicillin | 41 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 33 | 29 |
| Fluconazole | Fluconazole | 33 | 22 |
| Latanoprost | Latanoprost | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | 12 |
| Valacyclovir | Valacyclovir Hcl | 30 | 12 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 11 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Humulin R | Insulin Regular, Human | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | 11 |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | 14 |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nystatin | Nystatin | 14 | 11 |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Rifampin | Rifampin | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Enbrel | Etanercept | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $169.85 · 7 records | Lundbeck LLC | Auvelity, MOUNJARO, Ozempic, Rybelsus, VRAYLAR, VYEPTI | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error